Skip to main navigation
TCR² Therapeutics
  • Our Science
  • Our Pipeline
  • Patients
    • Clinical Trials
    • Expanded Access Program
  • Investors
    • Press Releases
    • SEC Filings
  • Get in Touch
  • Join Us
  • Home
  • Our Science
  • Our Pipeline
  • Patients
    ►
      ◄ Back
    • Clinical Trials
    • Expanded Access Program
  • Investors
    ►
      ◄ Back
    • Press Releases
    • SEC Filings
  • Get in Touch
  • Join Us

Investors & Media

Press Releases

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Nov 09, 2017

TCR² Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

Nov 02, 2017

TCR² Therapeutics Appoints Cell Therapy Pioneer Dr. Stephan Grupp to Advisory Board

Oct 31, 2017

TCR² Therapeutics to Present New Data from its TRuC™ T Cell Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 11, 2017

TCR² Therapeutics Appoints Leading Cell Therapy Expert as Chief Medical Officer

Sep 15, 2017

TCR² Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology Frontiers

Aug 29, 2017

TCR² Therapeutics to Present Solid Tumor Data at CAR-TCR Summit and CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Aug 08, 2017

TCR² Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Jun 13, 2017

TCR² Therapeutics Presents Positive Solid Tumor Data for its Novel TRuC™ Engineered T Cell Therapies at the World Preclinical Congress

May 16, 2017

TCR² Therapeutics to Present at the 2017 UBS Global Healthcare Conference

Feb 28, 2017

TCR² Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

  • Our Science
  • Our Pipeline
  • Patients
  • Investors
  • Get in Touch
  • Join Us
  • Privacy Policy
  • Disclaimer
  • Terms of Use
  • Supply Terms

© 2023 TCR² Therapeutics. All rights reserved.

TCR² Therapeutics